Diabetes Drug Class Appears to Reduce Recurrent Gout Flares
Previously associated with a lower incidence of gout, sodium-glucose cotransporter-2 (SGLT2) inhibitors for the first time also appear to reduce gout flare recurrence and excess mortality.
Stay updated with breaking news from Linical Studies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Previously associated with a lower incidence of gout, sodium-glucose cotransporter-2 (SGLT2) inhibitors for the first time also appear to reduce gout flare recurrence and excess mortality.
The findings are important for the older patient population who "typically face unique treatment challenges," the authors write.
'This is a population that has not gotten a lot of attention,' said an expert. Upgrading their pacemakers to a cardiac resynchronization device may be the answer for some.
A systematic approach to cardiovascular disease screening in adults with type 2 diabetes, COPD, or both led to more than doubling the rate of new CVD cases found compared with usual care.
Research-associated payments dipped by 24% from 2014 to 2022, new data suggest.